During the Ebola outbreak in 2014-2015 in Sierra Leone, residual clinical specimens and accompanying data were collected from routine diagnostic testing in Public Health England (PHE) led laboratories. Most of the samples with all the accompanying data were transferred to PHE laboratories in the UK for curation by PHE. The remainder have been kept securely in Sierra Leone. The biobank holds approximately 9955 samples of which 1108 tested positive for Ebola virus. Researchers from the UK and overseas, from academia, government other research organisations and commercial companies can submit proposals to the biobank to access and use the samples.
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Establishment of the MOHS-PHE Ebola Biobank
This biobank is a secure but accessible resource of biological samples that are essential for understanding human disease and the development of vaccines, diagnostics and treatments. The biobank samples are an especially valuable and finite resource, a legacy of the world's largest ever outbreak of Ebola virus disease. Outbreaks of this disease continue in Africa, so it is evident that further biomedical research is required to more readily bring outbreaks under control. The existing materials are also a record of other diseases that were incident in the population concurrently with Ebola. The EBGG guarantees equality of access to the materials and data for researchers from developed as well as low-and middle-income countries. It ensures that the resource is used for the global public good in accordance with the undertaking given by PHE to the MOHS, and that the research will have relevance to the people of Sierra Leone.
The biobank is accessible to all researchers globally from academia, government other research organisations and commercial companies. Because the samples were collected during an outbreak-where the primary objectives were to deliver care and limit the outbreak-ethical approval for research was not collected from patients. So, in addition to EBGG approval, researchers wishing to use its samples need to obtain ethical approval from the Sierra Leone national ethics committee and from a local institutional ethics committee prior to receiving their samples. Researchers can only access fully anonymised samples which are released with a material transfer agreement that guarantees the rights of the Sierra Leone government to any intellectual property developed during the research study and ensures the publication of all research results.
Samples and associated data
The 9955 samples comprise whole blood, blood plasma and swabs; 1108 of these tested positive for Ebola virus. Results are available for malaria testing but there are no results available for testing for other diseases that may have been carried by patients. All biobank samples are held in freezers at −80°C.
A database was established at PHE to store the associated data. Not all the samples have a full dataset, but the information in Box 1 is available for some samples in the biobank Currently there are no patient outcome details, but it is expected that this information will be available for inclusion in the database in the future. Until then it is possible for researchers to infer patient outcome by looking at sequential diagnostic tests.
Usually most samples are collected for inclusion in biobanks in accordance with protocols designed to guarantee consistency and high quality. They are also handled, processed and stored in ideal conditions. As the MOHS-PHE biobank comprises residual materials that were used for diagnosis there is variation in sample quality. Prior to their movement to PHE facilities, the samples may have been subjected to different storage conditions depending upon available facilities. Some had to be transported long distances to centres for testing and may have been subjected to cycles of freezing and thawing. The conditions the samples have been held in since their arrival in the UK in 2015 are fully documented. Samples are provided to researchers with the caveat that their quality cannot be guaranteed.
Variability in the quality of the diagnostic assays used during the outbreak has led to some samples being incorrectly classified and many of the samples may contain other undiagnosed pathogens. All samples are assumed to be highly infectious and will only be released, without further treatment, to researchers with documented access to Biosafety Level 4 facilities when all the appropriate permits are in place. Samples may be released when the risk of them containing live virus has been eliminated using a validated inactivation procedure. The method of virus inactivation is discussed with the receiving researcher and currently has involved the use of a commercial RNA/DNA extraction kit. We plan to use X-ray radiation for inactivation at some point in the future.
Applying to the MOHS-PHE Ebola Biobank
The EBGG seeks to collaborate with bona fide researchers wishing to undertake research that is in the public good and that will inform future healthcare and public health strategies in Sierra Leone. Application to the biobank is a one stage process made to the MOHS-PHE EBGG.
The biobank is a limited resource so research projects for which the scientific value has been scrutinized through peer review organised by a known organisation are prioritised. The amount and nature of depletable sample required is considered carefully and must be justified within the application in relation to the intended use. The EBGG secretariat maintains contact with the recipient research groups to ensure the materials are used for the intended health-related purposes and the Group will assess if the research use meets the required criteria for access (including legal and ethics standards). Researchers will also need to show that they have sufficient funding to cover the cost of preparing and delivering samples as well as research costs. For applications involving researchers from low and middle-income countries, this criterion may be waived. Applicants wishing to access materials are advised to contact PHE to confirm sample availability before their project plans are finalised.
Current research
The following research collaborations are ongoing:
Colonel Professor F. Sahr, Military Hospital, Freetown, Sierra Leone & Dr Felicity Fitzgerald UCL

The identification of the pathogens underlying febrile illnesses in children attending Ebola Holding Units testing negative for Ebola to identify opportunities for improving clinical outcomes
Stored plasma from children who tested negative for Ebola will be tested to identify pathogens in children with febrile illnesses. Understanding of the epidemiology of the commonest pathogens will allow the ruling out of Ebola infection and the delivery of targeted therapy. It will also inform future public health planning.
Professor Michael Levin & Dr Nathalie MacDermott, Imperial College London
Exploring the genetic factors that play an important role in susceptibility, severity and outcome from infectious disease There is growing evidence that exposure to Ebola results in different outcomes, from contacts remaining uninfected to severe, fatal infection. Among survivors some recover fully, others have virus persistence and others develop long term complications such as arthritis and uveitis. Identification of the genetic basis for susceptibility severity and outcome of Ebola will provide further information on its pathogenesis and new targets for therapy.
Dr Christopher H. Logue & Ms Emma Wise, PHE
Comparison of the viromes (collection of viruses) of Ebola negative and Ebola positive patients to establish the role that non-VHF pathogen co-infection may play in affecting clinical outcome and survival.
Significant developments have been made in the understanding the biology of Ebola but there remain gaps in our knowledge of the effects of co-infection with pathogens that co-circulate during an Ebola outbreak, and the role that pathogen co-infection may play in affecting clinical outcome and survival remains largely unknown. We hypothesize that the clinical outcome of patients infected with Ebola was detrimentally affected by co-infection with other circulating pathogens.
Dr Robert Watson, PHE Ebola MoDRAD
The development and delivery of a rapid and bedside diagnostic tool to significantly increase the capacity to handle future Ebola outbreaks The overall aim of Ebola MoDRAD is to develop and deliver rapid and bedside diagnostic tool(s), by way of a multidisciplinary research consortium drawn from key European and African research organisations.
The requested samples will be used to improve and validate the following rapid point-of-care diagnostics for use in the field:
• Validation of an Ebola blood inactivation tube for serology.
• IgM (IgG) antigen microarray epitope mapping of patient sera
• Validation of an Ebola antigen / IgM antibody lateral flow device
• Validation of rapid point-of-care isothermal assay
The future of the MOHS-PHE Ebola Biobank PHE's work includes a commitment to support research into the effective management of future disease outbreaks. The MOHS-PHE Ebola Biobank is unique in the UK in being housed in facilities suitable for the storage and processing of high-risk biological samples that require specialist handling by highly trained competent staff in appropriate Advisory Committee on Dangerous Pathogens hazard group 4 laboratories. Within these facilities, protocols are used for the inactivation of Ebola virus and other high-risk pathogens potentially contained in the samples, so they may be shared with researchers globally who lack access to such facilities. Therefore, the governance, management, laboratory processing and sharing of biobank resources have been detailed and documented. They can be re-employed by PHE or any other relevant organisation dealing with specimens that might be collected during any future infectious disease outbreak.
So, while the current biobank holdings are intended to be depleted by sharing with researchers, its laboratory and contextual legacy will be sustained. PHE is continuing to explore additional innovative and efficient ways to ensure researcher safety when dealing with highly dangerous viral pathogens so that high quality research may proceed. Additionally, planning is underway to include biobank operation and management as an element of laboratory training for Sierra Leone staff who may then more effectively undertake investigations on residual diagnostic samples.
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Introduction
The Introduction should have some reference(s) relating to the 2013-2015 Ebola outbreak to allow some readers who may be interested or lack the background information about this outbreak to gain deeper insight of this epidemic.
It would also be better to mention (along with an appropriate reference) of the availability of other Ebola biobanks, which are publicly accessible. If such a biobank is not available, an indication that this is the first of its kind would strengthen this section.
It is better to have a comma after the year 2015 in this sentence "In 2015 approximately…".
Establishment of the MOHS-PHE Ebola Biobank
In this section, the above title is a bit misleading in that what is described is some background on the West African Ebola outbreak and the establishment of the Ebola Biobank Governance Group (EBGG). Furthermore, the governance and modalities of accessing the samples are described. Meanwhile, information regarding the actual establishment of the biobank has not been described. I would suggest that this section be divided into two sections: one that describes how the biobank was established and the other which describes the governance and modalities of accessing and utilization of the biobank.
It is better to place a comma after the word "secure" in the sentence "This biobank is a secure but accessible…"
An appropriate reference is needed for this sentence "a legacy of the world's largest ever outbreak of Ebola virus disease". Some readers would be interested in the scale of other Ebola virus outbreaks.
It would be better to support the following sentence with a reference: "Outbreaks of this disease continue in Africa,…". An article describing the current ongoing Ebola outbreak in the Democratic Republic of Congo could be used.
Samples and associated data
The following sentence can be revised to improve clarity "Results are available for malaria testing but there are no results available for testing for other diseases that may have been carried by patients". Authors can consider something like "Laboratory results are available for malaria testing, but not for other diseases that may have afflicted Ebola virus disease patients".
In the sentence "All biobank samples are held in freezers at −80°C," the word "held" can be replaced with the word "stored."
I suggest that the whole of the sentence "Until then it is possible for researchers to infer patient outcome by looking at sequential diagnostic tests" be deleted. Such inferences may be erroneous.
Applying to the MOHS-PHE Ebola Biobank
Being a co-owned biobank, it would be better that applicants contact an overarching body rather than just PHE as suggested by this sentence "Applicants wishing to access materials are advised to contact PHE to confirm sample availability before their project plans are finalised".
Is the rationale for the Open Letter provided in sufficient detail?
